Encorium Group Inc. 

(Public, NASDAQ:ENCO)   Watch this stock   
Find more results for ENCO
Nov 16, 2009
Q3 2009 Earnings Release
Aug 24, 2009
Q2 2009 Earnings Release
More events from AOL Finance »    

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -24.06% -58.68%
Operating margin -24.04% -59.25%
EBITD margin - -54.52%
Return on average assets -32.74% -71.90%
Return on average equity -187.63% -149.02%
Employees 226 -

Address

One Glenhardie Corp. Center 1275 Drummers Lane, Suite 100
Wayne, PA 19087
United States - Map
+1-610-9759533 (Phone)
+1-610-9759556 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Options - Morningstar
Research Reports - Yahoo Finance

Encorium Group Inc. discussed on blogs

Ranking 1100+ Micro Cap Stocks by Upside Potential - NASD100.com ... - Investor's Resources - NASD100.com - Daily Stock Rankings - Nov 20, 2009

Encorium Group Inc. discussions

  View all discussions »

Description

Encorium Group, Inc. is a clinical research organization (CRO), which is engaged in the design and management of clinical trials for the pharmaceutical, biotechnology and medical device industries. The Company’s clients consist of companies in the pharmaceutical, biotechnology and medical device industries. The Company offers a range of clinical research and development services supporting Phase I through Phase IV clinical trials, such as strategic trial planning, project management, monitoring, data management and biostatistics, pharmacovigilance, medical writing, quality assurance, outsourcing of clinical staff and medical device certification in the European Union. The Company’s services include study protocol design, clinical trials management, global data management services, biostatistics, medical and regulatory affairs, quality assurance and compliance and medical report writing.

Officers and directors

Kai Lindevall M.D., Ph.D.
President, European and Asian Operations; Chairman of the Board
Age: 58
Bio & Compensation - Reuters
Philip L. Calamia
Interim Chief Financial Officer
Age: 46
Bio & Compensation - Reuters
Petri Manninen
Director
Age: 39
Bio & Compensation - Reuters
David Morra
Director
Age: 53
Bio & Compensation - Reuters
Shahab Fatheazam
Director
Age: 58
Bio & Compensation - Reuters
Sari Laitinen
Director
Age: 43
Bio & Compensation - Reuters